 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
13 News |  |
| «123» |
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Biomarker, Trial primary completion date: INSIGHT: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Jan 20, 2021
P2, N=24, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2022 --> Jul 2023
- || bersacapavir (JNJ-56136379) / J&J
Trial completion date, Trial primary completion date: A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants (clinicaltrials.gov) - Jan 20, 2021
P1, N=64, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2022 --> Jul 2023 Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Feb 2021 --> Jul 2021
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
New P2 trial: PENGUIN: A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Dec 13, 2020
P2, N=20, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Biomarker, New P2 trial: INSIGHT: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Oct 14, 2020
P2, N=24, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- JNJ-56136379 / J&J
[VIRTUAL] VIRAL SEQUENCE ANALYSIS OF CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH THE CAPSID ASSEMBLY MODULATOR (CAM-N) JNJ-56136379 (JNJ-6379) AS MONOTHERAPY IN THE ONGOING JADE PHASE 2a STUDY () - Oct 11, 2020 - Abstract #AASLD2020AASLD_856;
P2a
ETV/TDF treatment (either as switch [75mg arm] or add-on [250mg arm], respectively]) was initiated in all monotherapy patients and resulted in HBV DNA declines. No VBT was observed during JNJ-6379+NA combination therapy.
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Enrollment open: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection (clinicaltrials.gov) - Sep 30, 2020
P2, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
No VBT was observed during JNJ-6379+NA combination therapy. Not yet recruiting --> Recruiting
- || bersacapavir (JNJ-56136379) / J&J
Trial primary completion date: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - Sep 28, 2020
P1/2, N=114, Completed, Sponsor: Arrowhead Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2019 --> Apr 2020
- |||| bersacapavir (JNJ-56136379) / J&J
Trial completion, Trial completion date, Combination therapy, Monotherapy: JADE: An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Sep 9, 2020
P2a, N=232, Completed, Sponsor: Janssen Sciences Ireland UC
Trial primary completion date: Sep 2019 --> Apr 2020 Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Aug 2020
- | bersacapavir (JNJ-56136379) / J&J
Enrollment open: A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants (clinicaltrials.gov) - Sep 2, 2020
P1, N=64, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Aug 2020 Not yet recruiting --> Recruiting
- || daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Enrollment closed: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Sep 1, 2020
P2b, N=130, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| bersacapavir (JNJ-56136379) / J&J
Trial completion, Trial completion date, Trial primary completion date: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - Aug 18, 2020
P1/2, N=114, Completed, Sponsor: Arrowhead Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial completion date: Sep 2020 --> Apr 2020 | Trial primary completion date: Jun 2020 --> Sep 2019
- || Clinical, Review, Journal: Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. (Pubmed Central) - Jul 29, 2020
Increasing the potential for HBsAg loss may result in more patients achieving functional cure. However, many knowledge gaps remain such as pharmacokinetics in those with HBV, cirrhosis and renal impairment but also the interaction potential between investigational therapies, risk-benefit profiles, and potential for drug interactions with medications used to treat comorbidities associated with aging.
- JNJ-56136379 / J&J
[VIRTUAL] Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data (Poster Area) - Jul 29, 2020 - Abstract #EASLILCI2020EASL-ILC-I-2052;
P2a, P2b
A mean 0.4 log10 IU/mL HBsAg decline with JNJ-6379 250mg+NA was seen in NT HBeAg+ pts. JNJ- 6379+NA was safe and well tolerated, supporting evaluation of JNJ-6379 in combination with an NA and the siRNA JNJ-73763989 in the ongoing Ph2 REEF-1 study (NCT03982186).
- | bersacapavir (JNJ-56136379) / J&J
New P1 trial: A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants (clinicaltrials.gov) - Jul 16, 2020
P1, N=64, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Enrollment closed: REEF-1: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Jul 9, 2020
P2b, N=471, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
JNJ- 6379+NA was safe and well tolerated, supporting evaluation of JNJ-6379 in combination with an NA and the siRNA JNJ-73763989 in the ongoing Ph2 REEF-1 study (NCT03982186). Recruiting --> Active, not recruiting
- | bersacapavir (JNJ-56136379) / J&J
Trial primary completion date: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 (clinicaltrials.gov) - Jul 7, 2020
P1, N=48, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2020 --> Dec 2020
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
New P2 trial: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection (clinicaltrials.gov) - Jun 18, 2020
P2, N=80, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || JNJ-56136379 / J&J
Clinical, PK/PD data, Journal: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects. (Pubmed Central) - Jun 12, 2020
P1
JNJ-6379 was well tolerated in this study. Based on the safety profile and plasma exposures of JNJ-6379 in healthy subjects, a dosing regimen was selected for Part 2 of this study in patients with chronic hepatitis B. This is anticipated to achieve trough plasma exposures of JNJ-6379 at steady state of more than three times the 90% effective concentration of viral replication determined in vitro.
- | bersacapavir (JNJ-56136379) / J&J
Trial completion date: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 (clinicaltrials.gov) - Jun 11, 2020
P1, N=48, Recruiting, Sponsor: Janssen Sciences Ireland UC
Based on the safety profile and plasma exposures of JNJ-6379 in healthy subjects, a dosing regimen was selected for Part 2 of this study in patients with chronic hepatitis B. This is anticipated to achieve trough plasma exposures of JNJ-6379 at steady state of more than three times the 90% effective concentration of viral replication determined in vitro. Trial completion date: Sep 2020 --> Dec 2020
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Trial completion date: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Jun 11, 2020
P2b, N=120, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial completion date: Sep 2020 --> Dec 2020 Trial completion date: Apr 2022 --> Aug 2022
- JNJ-73763989 / J&J, JNJ-56136379 / J&J, JNJ-3989 / J&J
First clinical experience with RNA interference [RNAi]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA) (Mengwi 3 Room) - Mar 9, 2020 - Abstract #APASL2020APASL_117;
- ||||| daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
New P2b trial: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Feb 27, 2020
P2b, N=120, Recruiting, Sponsor: Janssen Sciences Ireland UC
- || daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Trial completion date: REEF-1: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Feb 19, 2020
P2b, N=450, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial completion date: Apr 2022 --> Aug 2022 Trial completion date: Nov 2022 --> Feb 2023
- || bersacapavir (JNJ-56136379) / J&J
Enrollment open: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 (clinicaltrials.gov) - Jan 29, 2020
P1, N=48, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial completion date: Nov 2022 --> Feb 2023 Not yet recruiting --> Recruiting
- || bersacapavir (JNJ-56136379) / J&J
New P1 trial: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 (clinicaltrials.gov) - Dec 22, 2019
P1, N=48, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- || bersacapavir (JNJ-56136379) / J&J
Trial completion date, Trial primary completion date: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - Dec 9, 2019
P1/2, N=102, Recruiting, Sponsor: Arrowhead Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Jan 2020 --> Sep 2020 | Trial primary completion date: Oct 2019 --> Jun 2020
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Enrollment open, Trial completion date: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Nov 27, 2019
P2b, N=120, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jan 2020 --> Sep 2020 | Trial primary completion date: Oct 2019 --> Jun 2020 Not yet recruiting --> Recruiting | Trial completion date: Nov 2022 --> Jan 2022
- || bersacapavir (JNJ-56136379) / J&J
Trial completion: A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants (clinicaltrials.gov) - Nov 27, 2019
P1, N=16, Completed, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting | Trial completion date: Nov 2022 --> Jan 2022 Active, not recruiting --> Completed
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Trial completion date: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Nov 15, 2019
P2b, N=120, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial completion date: Jan 2022 --> Nov 2022
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
New P2b trial: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Oct 16, 2019
P2b, N=120, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- JNJ-73763989 / J&J, JNJ-56136379 / J&J, JNJ-3989 / J&J
FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA) (Hynes Convention Center, Hall B) - Oct 15, 2019 - Abstract #AASLD2019AASLD_3157;
This is the first study to investigate the safety and efficacy of a triple combination of a RNAi (JNJ-3989), a CAM-N (JNJ-6739) and a NA in CHB pts. This combination was well tolerated and pts achieved robust reductions in HBsAg as well as other measurable viral parameters.
- | bersacapavir (JNJ-56136379) / J&J
Enrollment closed: A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants (clinicaltrials.gov) - Oct 1, 2019
P1, N=16, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
This combination was well tolerated and pts achieved robust reductions in HBsAg as well as other measurable viral parameters. Recruiting --> Active, not recruiting
- | daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
Enrollment open: REEF-1: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Aug 14, 2019
P2b, N=450, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | bersacapavir (JNJ-56136379) / J&J
Trial completion: A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants (clinicaltrials.gov) - Jul 11, 2019
P1, N=6, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- || bersacapavir (JNJ-56136379) / J&J
Enrollment open: A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants (clinicaltrials.gov) - Jun 16, 2019
P1, N=16, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| daplusiran/tomligisiran (GSK5637608) / GSK, bersacapavir (JNJ-56136379) / J&J
New P2b trial: REEF-1: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Jun 11, 2019
P2b, N=450, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- || bersacapavir (JNJ-56136379) / J&J
New P1 trial: A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants (clinicaltrials.gov) - May 9, 2019
P1, N=16, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- || bersacapavir (JNJ-56136379) / J&J
Trial primary completion date: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - May 2, 2019
P1/2, N=102, Recruiting, Sponsor: Arrowhead Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2019 --> Oct 2019
- | bersacapavir (JNJ-56136379) / J&J
Enrollment open: A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants (clinicaltrials.gov) - Apr 29, 2019
P1, N=6, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2019 --> Oct 2019 Not yet recruiting --> Recruiting
- ||| bersacapavir (JNJ-56136379) / J&J
Enrollment closed, Combination therapy, Monotherapy: JADE: An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Apr 18, 2019
P2a, N=232, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | bersacapavir (JNJ-56136379) / J&J
New P1 trial: A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants (clinicaltrials.gov) - Mar 6, 2019
P1, N=6, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | bersacapavir (JNJ-56136379) / J&J
Enrollment change, Trial completion date: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - Oct 24, 2018
P1/2, N=86, Recruiting, Sponsor: Arrowhead Pharmaceuticals
Recruiting --> Active, not recruiting N=60 --> 86 | Trial completion date: Mar 2019 --> Jan 2020
- | bersacapavir (JNJ-56136379) / J&J
Trial completion: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) (clinicaltrials.gov) - Jul 10, 2018
P1, N=87, Completed, Sponsor: Janssen Sciences Ireland UC
N=60 --> 86 | Trial completion date: Mar 2019 --> Jan 2020 Recruiting --> Completed
- || bersacapavir (JNJ-56136379) / J&J
Trial completion date, Combination therapy, Monotherapy: JADE: An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Apr 27, 2018
P2a, N=220, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed Trial completion date: Jun 2020 --> Mar 2021
- |||| bersacapavir (JNJ-56136379) / J&J
Enrollment open: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - Mar 12, 2018
P1/2, N=60, Recruiting, Sponsor: Arrowhead Pharmaceuticals
Trial completion date: Jun 2020 --> Mar 2021 Not yet recruiting --> Recruiting
- ||| bersacapavir (JNJ-56136379) / J&J
Trial initiation date: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - Mar 9, 2018
P1/2, N=60, Not yet recruiting, Sponsor: Arrowhead Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Mar 2018 --> Mar 2018
- || bersacapavir (JNJ-56136379) / J&J
Trial completion date, Trial initiation date, Trial primary completion date: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) (clinicaltrials.gov) - Mar 3, 2018
P1, N=84, Recruiting, Sponsor: Janssen Sciences Ireland UC
Initiation date: Mar 2018 --> Mar 2018 Trial completion date: May 2018 --> Oct 2018 | Initiation date: Dec 2015 --> Dec 2015 | Trial primary completion date: May 2018 --> May 2018
- |||| bersacapavir (JNJ-56136379) / J&J
Enrollment open, Trial initiation date, Combination therapy, Monotherapy: JADE: An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Feb 28, 2018
P2a, N=220, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial completion date: May 2018 --> Oct 2018 | Initiation date: Dec 2015 --> Dec 2015 | Trial primary completion date: May 2018 --> May 2018 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018
- || bersacapavir (JNJ-56136379) / J&J
Trial primary completion date: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) (clinicaltrials.gov) - Dec 11, 2017
P1, N=84, Recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018 Trial primary completion date: Nov 2017 --> May 2018
- ||||| bersacapavir (JNJ-56136379) / J&J
New P1/2 trial: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) (clinicaltrials.gov) - Dec 8, 2017
P1/2, N=60, Not yet recruiting, Sponsor: Arrowhead Pharmaceuticals